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Prostate cancer growth patterns beyond the Gleason score: entering a new era of compre-
hensive tumour grading
The Gleason grading system is one of the most impor-
tant factors in clinical decision-making for prostate
cancer patients, and is entirely based on the classifi-
cation of tumour growth patterns. In recent years it
has become clear that some individual growth pat-
terns themselves have independent prognostic value,
and could be used for better personalised risk
stratification. In this review we summarise recent lit-
erature on the clinicopathological value and molecu-
lar characteristics of individual prostate cancer
growth patterns, and show how these, most particu-
larly cribriform architecture, could alter treatment
decisions for prostate cancer patients.
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Introduction
The Gleason grading system is important for determin-
ing prostate cancer prognosis and for clinical decision-
making. The Gleason score is entirely based on the
classification of adenocarcinoma growth patterns.
These patterns are assigned a Gleason grade from 1 to
5. As prostate cancer is such a heterogeneous disease,
the Gleason score is determined by adding together
the most common grade and the highest grade in
biopsies, and the two most predominant grades in rad-
ical prostatectomy (RP) specimens.1,2 Gleason patterns
1–3 encompass well-delineated glandular structures
with variable interglandular distances and nodular cir-
cumscription. As no practical and prognostic differ-
ences exist between these three Gleason grades, the
International Society of Urological Pathology (ISUP)
has recommended that Gleason scores 2–4 should
rarely, if ever, be used for biopsy specimens.2 Gleason
pattern 4 comprises poorly formed, fused, glomeruloid
and cribriform glandular structures, whereas growth
patterns with essentially no glandular differentiation,
such as single cells, cords, and solid fields, and the
presence of comedonecrosis are classified as Gleason
pattern 5 (Figure 1).2,3 Individual growth patterns
have, in general, not been specified in pathology
reports or in molecular–biological investigations. How-
ever, recent studies have indicated that individual
growth patterns have independent predictive value for
clinical outcome, and facilitate more comprehensive
interpretation of molecular–biological findings. The
aims of this review are to summarise the clinicopatho-
logical impact of individual prostate cancer growth
patterns beyond the Gleason score, and to investigate
their molecular–biological background. We show how
consideration of growth patterns could optimise deci-
sion-making in clinical practice.
Clinicopathological impact of individual
growth patterns
Individual tumour growth patterns have mainly been
analysed in Gleason score 3 + 4 = 7 (Grade Group 2)
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prostate cancer, which is composed of variable quan-
tities of well-delineated Gleason pattern 3 glands and
Gleason pattern 4 structures. In 2011, Iczkowski
et al. were the first to report that a cribriform growth
pattern had independent prognostic value for postop-
erative biochemical recurrence.4 Many groups have
since confirmed the independent predictive value of a
cribriform pattern for adverse pathological features,
biochemical recurrence-free survival and disease
specific survival in biopsy and RP specimens.5–15
Whereas the value of cribriform architecture has
mostly been investigated in Gleason score 7 prostate
cancer, it also affects cancer-specific survival for
patients with Gleason score 8 (Grade Group 4) biop-
sies.11,16 A limitation of many studies on cribriform
growth pattern, however, is that it is not entirely
clear whether, and if so how, an invasive Gleason
pattern 4 pattern was distinguished from intraductal
carcinoma (IDC) of the prostate.
IDC is characterised by a cribriform or solid prolif-
eration of atypical epithelial cells within distended
pre-existing prostate acini, either with or without
comedonecrosis, and has also been associated with




G HFigure 1. Overview of Gleason
growth patterns. A, Gleason
pattern 3 well-delineated
glands. B–E, Gleason pattern 4
poorly formed (B), fused (C),
glomeruloid (D) and cribriform
(E) architecture. F–H, Gleason
pattern 5 single cells/cords (F),
solid sheets (G), and
comedonecrosis (H).
Haematoxylin and eosin.
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 850–861.
Prostate cancer growth patterns 851
majority of patients, IDC occurs intermixed with inva-
sive carcinoma, but rare cases of isolated IDC without
invasive disease have been described.22 These rare
cases of isolated IDC should not be graded, but a
comment should indicate their association with
unsampled high-grade carcinoma.1,3,22,23 The finding
of isolated IDC on needle biopsy should lead to imme-
diate re-biopsy, and some even advocate radical treat-
ment in these cases.22 The International Society of
Urological Pathology (ISUP) recommended in 2014
and the World Health Organization (WHO) recom-
mended in 2016 that the presence of IDC without
invasive carcinoma should be specifically mentioned,
but no recommendations were made for reporting of
IDC admixed with invasive cancer.1,3
Invasive cribriform carcinoma and IDC are often
difficult, if not impossible, to distinguish without the
application of basal cell immunohistochemistry. If no
basal cells are present, a cribriform lesion is generally
considered to be invasive Gleason pattern 4; if contin-
uous, scattered or sporadic basal cells are observed,
cribriform architecture is mostly regarded as IDC.
Only a few studies have attempted to investigate
invasive cribriform carcinoma and IDC separately by
using extensive immunohistochemistry.11,15,24 In a
prostate biopsy screening cohort of 1031 men, Kwel-
dam et al. found that the presence of invasive cribri-
form carcinoma and the presence of IDC were both
associated with worse disease-specific survival in uni-
variate analyses.11 The two combined showed the
strongest association with outcome in this study. At
the most recent ISUP consensus meeting in Nice,
France, 2019, it was agreed that both invasive cribri-
form carcinoma and IDC should be specifically
reported.23
The grading of IDC intermixed with invasive carci-
noma has been controversial. Whereas the 2014
ISUP meeting did not make a recommendation on
this issue, in 2016 the WHO stated that it should not
be factored into grading.1,3 A consequence of the
WHO recommendation is that basal cell immunohis-
tochemistry should be performed in every case in
which IDC cannot be distinguished from invasive dis-
ease and classification as either IDC or invasive carci-
noma will alter the final Gleason score. Apart from
additional turnaround time and costs, basal cell
immunohistochemistry does not distinguish between
IDC and invasive cribriform or solid carcinoma in
every case. It is well known that foci of high-grade
prostate intraepithelial neoplasia can lack basal cells,
probably because of sampling artefact; as IDC glands
are, by definition, distended, the chance of a false-
negative basal cell immunohistochemical result is
likely to be even larger, resulting in erroneous classifi-
cation as an invasive cribriform pattern. On the other
hand, large irregular cribriform tumour fields sub-
stantially exceeding the pre-existing gland architec-
ture and thus clearly invasive may have occasional
basal cells, as has also been reported on rare occa-
sions for low-grade invasive adenocarcinoma.25 As
IDC is an adverse pathological parameter, and diffi-
cult or even impossible to distinguish from invasive
carcinoma even with the use of basal cell immunohis-
tochemistry, it was recommended at the latest 2019
ISUP consensus meeting that IDC intermixed with
invasive carcinoma should be assigned a Gleason
grade based on its underlying growth pattern, as if it
were invasive carcinoma.23 On the other hand, the
Genitourinary Pathology Society (GUPS) recommends
not factoring IDC into Gleason grading, and perform-
ing basal cell immunohistochemistry if classification
as either invasive carcinoma or IDC would lead to a
change in the final Gleason score.26 Thus, a Gleason
score 6 prostate cancer biopsy with a cribriform
lesion is now classified as Grade Group 2 according to
the 2019 ISUP recommendation, without immuno-
histochemistry; the GUPS recommends performing
basal cell immunohistochemistry and grading the
tumour as Grade Group 1 if basal cells are present
and as Grade Group 2 if they are not. Both the ISUP
and the GUPS recommend including a comment on
the association of IDC with aggressive disease,
whereas the vast majority of genitourinary patholo-
gists consider the above-mentioned case not to be eli-
gible for active surveillance.27 Inclusion or exclusion
of IDC in tumour grading results in a global Grade
Group shift in < 2% of prostate cancer biopsies.28,29
Clinical implications
As both cribriform invasive carcinoma and IDC have
independent predictive value, the presence of either of
them should routinely be reported as ‘cribriform car-
cinoma’. The question arises as to what extent the
absence or the presence of cribriform carcinoma can
lead to optimisation of therapeutic decision-making
for individual prostate cancer patients. Patients with
biopsy Gleason score 3 + 4 = 7 (Grade Group 2) dis-
ease will generally be offered definitive treatment,
whereas those with Gleason score 3 + 3 = 6 (Grade
Group 1) disease are often eligible for active surveil-
lance. The recent identification of additional prognos-
tic pathological parameters, such as the presence of
invasive cribriform carcinoma and/or IDC and the
quantity of Gleason pattern 4, allows for more
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detailed risk stratification of patients with Grade
Group 2 disease. Patients with a small quantity of
Gleason pattern 4 in the biopsy may be eligible for
active surveillance, as their outcome is comparable to
that of those with Grade Group 1 disease. The sub-
stantial interobserver variability for grade assignment
for small foci of poorly formed and fused glands could
be another argument for this strategy.30–35 Disease-
specific and biochemical recurrence-free survival are
not statistically significantly different between patients
with Grade Group 2 disease without cribriform carci-
noma on biopsy and those with Grade Group 1 dis-
ease, and it has therefore been proposed that the
absence of both invasive cribriform carcinoma and
IDC may qualify a patient with Grade Group 2 disease
on biopsy for active surveillance.10,11,36,37 If the
safety of this eligibility approach is demonstrated in
prospective studies, it will have a major impact on
the management of patients with Grade Group 2 dis-
ease. The presence of cribriform carcinoma may also
affect other aspects of clinical decision-making; the
absence of cribriform architecture has been associated
with a low risk of pelvic lymph node metasta-
sis.13,38,39 In a series of 627 RP specimens, 22 of
228 (10%) patients with Grade Group 2 disease with
cribriform carcinoma developed metastases, whereas
no metastases were observed among 192 patients
with cribriform-negative Grade Group 2 disease and
207 patients with Grade Group 1 disease.38 Current
guidelines for performing pelvic lymph node dissec-
tions (PLNDs) are based on clinicopathological nomo-
grams that do not take into consideration cribriform
architecture, but the future inclusion of invasive crib-
riform carcinoma and IDC may optimise these nomo-
grams. A few studies have also found independent
value for cribriform carcinoma with respect to radia-
tion therapy or response to docetaxel, but the defini-
tive clinical impact on these treatment modalities
remains to be determined.19,40,41
As invasive cribriform carcinoma and IDC may
increasingly influence clinical decision-making, the
sensitivity for detection of these adverse features on
biopsy should ideally be high. Concordance between
Grade Group in RP specimens and in matched biop-
sies is relatively low, with tumour upgrading occur-
ring in up to 40% of cases. As compared with RP
specimens, the sensitivity and specificity for identifica-
tion of invasive cribriform carcinoma and/or IDP in
biopsy specimens vary from 43% to 56% and from
87% to 95%, respectively.42–44 This indicates that
approximately half of cribriform carcinoma lesions
are missed in diagnostic biopsies. Detailed analysis of
features potentially associated with false-negative
reporting of cribriform growth on biopsies did not
reveal any association with the number of positive
biopsies, the percentage of Gleason pattern 4 or the
presence of glomeruloid architecture in a relatively
small series.43 On the other hand, multiparametric
magnetic resonance imaging (MRI) may have added
value for the identification of patients with prostatic
invasive cribriform carcinoma and IDC that has not
been identified on the biopsy, owing to sampling
error. Many of these lesions show Prostate Imaging
Reporting and Data System score 5 MRI abnormali-
ties.43,45,46 Finally, commercially available molecular
tests might also play a role in the identification of
patients with these adverse features; this is discussed
in more detail later.47–49
Invasive cribriform growth pattern
delineation
As invasive cribriform carcinoma should be sepa-
rately commented on in pathology reports and may
increasingly affect therapeutic decision-making, it is
important to delineate this growth pattern and sepa-
rate it from its microscopic mimics.23 Here, we will
only consider other invasive acinar tumour growth
patterns that might be confused with a cribriform
pattern; for the broad differential diagnosis of cribri-
form architecture including benign mimics, we refer
to some excellent reviews on this subject.50–52 The
adjective ‘cribriform’ is a combination of the Latin
words cribrum (sieve) and forma (likeness), and refers
to sheets of epithelial cells punctuated by gland-like
spaces. Recognition of cribriform and glomeruloid
growth patterns is better than for poorly formed and
fused glands of Gleason pattern 4.35,53,54 Neverthe-
less, tangentially sectioned tumour glands, complex
fused glands, large glomeruloid structures and solid
Gleason pattern 5 might all be confused with an
invasive cribriform pattern.54 As cribriform morphol-
ogy might affect clinical decision-making, and to
allow for comparison in future studies, a clear defini-
tion of cribriform pattern is essential. Our group has
defined cribriform architecture as an epithelial sheet
(a) in which the majority of tumour cells do not con-
tact the surrounding stroma, (b) with a gland-like
space surrounding less than half of the sheet circum-
ference, and (c) with regular intercellular lumens
clearly visible on haematoxylin and eosin (H&E)-
stained sections (Figure 2).55,56 The first criterion (a)
distinguishes a cribriform pattern from complex fused
glands in which most if not all tumour cells are still
in direct contact with subtle connective tissue cores
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present within the lesion. The second criterion (b)
arbitrarily distinguishes a cribriform from a large
glomeruloid pattern in which gland-like spaces sur-
round more than half of the central protrusion. The
validity of this criterion is supported by the fact that
the clinicopathological features and biochemical
recurrence-free survival of patients with large
glomeruloid structures on RP were more comparable
to those of small glomeruloid structures than of crib-
riform Gleason pattern 4.57 The third criterion (c) dis-
tinguishes cribriform from solid Gleason pattern 5, in
which essentially no glandular differentiation is visi-
ble on H&E-stained sections. With respect to the lat-
ter, it should be noted that the presence of
intracytoplasmic vacuoles should be ignored for
tumour grading, in contrast to lumen formation
between two or more individual tumour cells.2
Although our H&E-based description is also mirrored
by the three-dimensional architectural characteristics
of individual prostate cancer growth patterns, a broad
consensus on the definition of cribriform morphology
and its unique features delineating it from its mimics
needs to be achieved.55
Clinical relevance of non-cribriform growth
patterns
Whereas invasive cribriform carcinoma and IDC have
independent value for predicting clinical outcome in
patients with Grade Group 2 disease, it is not yet
entirely clear to what extent the outcomes of patients
with Grade Group 2 disease without cribriform archi-
tecture differ from those of patients with Grade Group
1 disease. With a median follow-up of 13 years,
Kweldam et al. did not find statistically different dis-
ease-specific survival rates for 256 patients with
biopsy cribriform-negative Grade Group 2 disease and
486 patients with Grade Group 1 disease.11 In a RP
cohort, Hollemans et al. did not find any metastasis
on PLND or during follow-up in 207 patients with
Grade Group 1 disease and in 197 patients with
Grade Group 2 disease without invasive cribriform
carcinoma and IDC.38 The latter group, however, had
significantly shorter biochemical recurrence-free sur-
vival than the former group. These data suggest that
cribriform architecture reflects an intrinsic capacity
for the development of metastasis, whereas the risk of
biochemical recurrence depends more on other fac-
tors, such as tumour volume, positive surgical mar-
gins, or non-cribriform Gleason patterns.
Because of its morphological resemblance to, and
frequent co-occurrence with, a cribriform pattern,
glomeruloid architecture has been classified as Glea-
son pattern 4 since the 2014 ISUP consensus meet-
ing.3 Some authors have postulated that it represents
a precursor of cribriform morphology.58 However, in
350 RP specimens with Gleason score 7, Choy et al.




complex fused GP 4
solid GP 5 large glomeruloid GP 4
Figure 2. Delineating features
of invasive cribriform
carcinoma. In cribriform
carcinoma: A, the majority of
tumour cells do not contact
the surrounding stroma,
whereas, in complex fused
glands, most epithelial cells are
adjacent to subtle connective
tissue cores; B, a gland-like
space surrounds less than half
of the sheet circumference,
whereas it encircles most of
the protrusion in glomeruloid
glands; and C, regular
intercellular lumens are clearly
visible as opposed to Gleason
pattern 5 solid sheets.
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increased the risk of biochemical recurrence, whereas
glomeruloid architecture was significantly associated
with a reduced risk.5 Among 472 Grade Group 2 RP
specimens, patients with cribriform morphology had
significantly worse clinicopathological features and
biochemical recurrence-free survival than those with
a glomeruloid pattern, irrespective of the size of the
glomerulations.57 These findings seem to be incom-
patible with the hypothesis that glomeruloid glands
are precursors of cribriform architecture.
With increasing awareness of their clinical impact,
proposals for the subclassification of some established
growth patterns have been made. In a detailed study
of 1275 RP specimens, McKenney et al. distinguished
20 different growth pattern features.14 This group
confirmed the adverse outcome associated with cribri-
form architecture as compared with poorly formed
glands. They also found that a reactive stroma
response was associated with worse recurrence-free
survival, whereas mucin extravasation was associated
with a better prognosis. More detailed analysis of
cribriform patterns has shown that the number of
cribriform fields does not seem to affect clinical out-
come in a negative way, whereas their maximal indi-
vidual size does.11,15,24 In 420 Grade Group 2 RP
specimens, tumours with large expansile cribriform
fields arbitrarily defined as exceeding at least two
times the size of adjacent benign glandular structures
showed seminal vesicle invasion in 32% of cases and
pelvic node metastasis in 23% of cases. This was sig-
nificantly higher than the 9% and 5%, respectively,
found with small fields of invasive cribriform carci-
noma.24 Other groups have also separated cribriform
patterns, but these studies are difficult to compare, as
they applied other size criteria, such as the presence
of at least 12 intercellular lumens or exceeding the
average diameter of benign glands.4,15,59 If the
adverse outcome associated with large expansile crib-
riform architecture can be confirmed by further stud-
ies, and consensus can be reached on its definition,
this could be another growth pattern that is indepen-
dently associated with clinical outcome and that
could potentially impact on treatment decisions.
There is still little known about the clinical rele-
vance of Gleason 5 growth patterns, which have been
classified as single cells, cords, solid fields, or the pres-
ence of comedonecrosis.1 This is mostly because
tumours with primary, secondary or tertiary Gleason
pattern 5 are very heterogeneous, with variable
quantities of Gleason patterns 3, 4, and 5, several dif-
ferent growth patterns, and the occurrence of IDC.
Meaningful statistical analysis including all relevant
covariates requires inclusion of a large number of
these patients. Nevertheless, the presence of come-
donecrosis and the presence of solid sheets were
found to be adverse parameters among Gleason 5
patterns in two relatively small series.60,61
Molecular aberrations in cribriform
architecture
Molecular alterations in prostate cancer have mostly
been examined according to the Gleason score, with-
out underlying growth patterns being taken into
account. Recently, a few groups have aimed to iden-
tify the molecular characteristics of invasive cribri-
form carcinoma and IDC.62–64 As these bioinformatic
analyses were performed retrospectively on publicly
available databases with digitally scanned H&E-
stained reference slides, no reliable distinction
between invasive cribriform carcinoma and IDC could
be made. Cribriform carcinoma showed an increased
percentage of genomic alterations, this being a sign
of genomic instability.62,63 Among others, deletions
of 8p and 10q and amplification of 8q24 correspond-
ing to PTEN loss and c-MYC gain were significantly
enriched in cribriform carcinoma, together with SPOP
point mutations.62–66 Molecular profiling and RNA
in-situ hybridisation revealed that the long non-cod-
ing RNA SChLAP1 had more than three-fold higher
levels in cribriform architecture, and could serve as a
potential marker for its detection in clinical prac-
tice.63,67 Interestingly, some of the molecular aberra-
tions associated with cribriform carcinoma have been
linked to aggressive clinical behaviour of prostate
cancer.68–73 Together, these data indicate that cribri-
form carcinoma is a morphological substrate of
increased genomic instability, and this brings
histopathology, molecular aberrations and adverse
clinical outcome together comprehensively.
Individual non-cribriform growth patterns in
patient samples have not been subjected to extensive
molecular profiling. In a growth pattern-based study
on epithelial–mesenchymal transition (EMT) reflected
by E-cadherin to N-cadherin switching in RP speci-
mens, Kolijn et al. showed that E-cadherin to N-cad-
herin switching mainly occurred in poorly formed
Gleason pattern 4 gland architecture.74 As EMT is
considered to be a reversible process, consecutive
mesenchymal–epithelial transition might be associ-
ated with E-cadherin up-regulation, N-cadherin
down-regulation, and the formation of mature Glea-
son pattern 3 tubules. With regard to the fact that
patients with non-cribriform Grade Group 2 disease
have a comparable low risk for metastasis to that of
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patients with Grade Group 1 disease, it is of interest
that molecular profiling did not reveal significant dif-
ferences in copy number alterations between these
two groups.62,75 On the basis of these clinical and
molecular data, we hypothesise that some growth
patterns, such as poorly formed Gleason pattern 4,
represent temporary morphological tumour states
reflecting dynamic tubular branching and elongation,
especially when they are admixed with Gleason pat-
tern 3 structures.76
Apart from the scientific point of view, identifica-
tion of a ‘cribriform signature’ could have substantial
relevance. As mentioned previously, the high rate of
false cribriform-negative biopsies might be a signifi-
cant limitation to developing clinical decision models
incorporating cribriform carcinoma. A clinically appli-
cable molecular urine, serum or tissue test might
identify patients at risk for unsampled cribriform car-
cinoma. In the past few years, RNA expression-based
tissue assays such as Decipher (GenomeDx Bio-
sciences Inc., Vancouver, BC, Canada), Oncotype Dx
(Genomic Health Inc., Redwood City, CA, USA) and
Prolaris (Myriad Genetics, Salt Lake City, UT, USA)
have become commercially available for clinical strat-
ification of patients with intermediate-risk prostate
cancer.77,78 Three recent studies have shown that
higher risk scores obtained with both the Decipher
and Oncotype Dx tests were significantly associated
with the presence of cribriform carcinoma in the tis-
sue sample analysed.47–49 These studies underscore
the importance of the recording of cribriform archi-
tecture in the pathology report, and suggest that crib-
riform morphology might substitute for some of the
information gained from these tests.47 It remains to
be determined whether these molecular assays will
still have added clinical value when cribriform carci-
noma and the percentage of Gleason pattern 4 are
taken into account, and whether they can identify
patients with false cribriform-negative prostate cancer
biopsies.
Three-dimensional architecture of prostate
cancer growth patterns
Microscopic diagnostic pathology in everyday practice
is performed with thin tissue slides representing two-
dimensional cross-sections of a three-dimensional
structure. Little is known about the actual three-di-
mensional architecture of prostate cancer growth pat-
terns. Reconstruction of hundreds of consecutive
slides has shown that poorly formed Gleason pattern
4 is continuous with Gleason pattern 3.79,80 Recent
improvements in tissue-clearing techniques, long-dis-
tance confocal laser scanning and light-sheet micro-
scopy have enabled the imaging of intact 1-mm-thick
prostate tissues.81–83 By detailed three-dimensional
analysis of formalin-fixed paraffin-embedded RP speci-
mens, we were able to gain comprehensive insights
into the three-dimensional architecture of prostate
adenocarcinoma growth patterns.55 This revealed
that Gleason pattern 3 three-dimensionally repre-
sented tubules with local interconnections. This pat-
tern was continuous with both poorly formed Gleason
pattern 4, in which tubular size and lumen diameter
were smaller and tubular interconnections occurred
more frequently, and fused Gleason pattern 4, in
which interconnections often occurred at distances
smaller than the tubular diameter. In fact, Gleason
pattern 5 single cells and cords formed a continuum
with poorly formed glands, in which lumen size fur-
ther decreased until lumens disappeared. On the other
hand, cribriform Gleason pattern 4 and solid Gleason
pattern 5 either with or without comedonecrosis con-
sisted of serpentine fields of epithelial cells, with the
majority of tumour cells not being in direct contact
with the surrounding stroma. Both patterns formed a
continuum with or without the presence of recognis-
able intercellular lumens. On the basis of these three-
dimensional features, we classified the growth pat-
terns in two distinct subgroups, which both formed
continua. The first group consisted of Gleason pattern
3 tubules, Gleason pattern 4 poorly formed and fused
glands, and Gleason pattern 5 single cells and cords,
which all consisted of cells directly contacting the sur-
rounding stroma, but with variable gland diameter,
lumen size, and number of interconnections. The sec-
ond group encompassed cribriform Gleason pattern 4
and solid Gleason pattern 5 with or without come-
donecrosis consisting of epithelial cells, in which the
majority of cells did not contact the adjacent stroma
and there were variable intercellular lumen frequen-
cies and sizes (Figure 3). Glomeruloid structures
formed a three-dimensional intermediate between
these two subgroups. They represented intraluminal
protrusions of epithelial cells appearing within a back-
ground of Gleason pattern 3 tubules, and were mostly
present at the sites of tubular interconnections. The
three-dimensional architectural continuity and transi-
tions between growth patterns in both subgroups
can, to a large extent, explain the interobserver vari-
ability in Gleason grading.53,84 Whereas growth pat-
terns are classified into separate Gleason grades in
clinical practice, in fact they gradually transition into
each other without the presence of clearly identifiable
cut-offs. Furthermore, the three-dimensional
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architectural relationships support the definition and
delineating characteristics of a cribriform growth pat-
tern, as mentioned previously. Future studies need to
determine whether this three-dimensional dichotomi-
sation is also reflected by clinical and molecular
observations.
GP 3 GP 5GP 4
fused
decreased tubule
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Figure 3. Schematic overview of the Gleason growth patterns in prostate cancer. Three-dimensionally, two morphological subgroups of
growth pattern are observed. Gleason pattern 3, poorly formed and fused Gleason pattern 4 and Gleason pattern 5 cords form the first sub-
group, in which the vast majority of the tumour cells make direct contact with the surrounding stroma. The second subgroup consists of
cribriform Gleason pattern 4 and solid Gleason pattern 5; the vast majority of tumour cells do not make contact with the surrounding
stroma. Comedonecrosis might be present in this subgroup. Glomeruloid structures represent a morphological intermediate pattern between
the two subgroups.
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Future perspectives
During the last decade, invasive cribriform carcinoma,
IDC, the percentage of Gleason pattern 4 and the pres-
ence of minor/tertiary high-grade Gleason patterns have
all been shown to be pathological factors with indepen-
dent prognostic value.23 In most studies, these parame-
ters have been investigated as solitary features without
inclusion of the other factors as covariates. It remains to
be determined whether each of these factors has inde-
pendent prognostic value in multivariable analysis. In a
study of 370 Grade Group 2 biopsies, Kweldam et al.
showed that 44% of patients with 25–50% Gleason pat-
tern 4 had invasive cribriform carcinoma or IDC,
whereas these patterns were present in only 6% of
patients with 1–10% Gleason pattern 4.85 In multivari-
able analysis, cribriform carcinoma was an independent
parameter for postoperative biochemical recurrence-free
survival, whereas the percentage of Gleason pattern 4
was not. Future multivariable analyses need to elucidate
the independent value of these recently established prog-
nostic pathological factors. After identification of the
independent, most influential and most reproducible fac-
tors, modification of the current Gleason grading/Grade
Group systems could even be considered to increase the
discriminative value of tumour grading.56,86 Further-
more, prospective studies including cribriform carci-
noma in clinical decision-making, e.g. when considering
eligibility for active surveillance, should indicate to what
extent growth pattern specification can optimise patient
management.
In conclusion, incorporation of individual growth
patterns in pathology reporting and clinical decision-
making has the potential to optimise personalised
treatment of prostate cancer patients. Investigation of
individual growth patterns beyond heterogeneous
Gleason groups allows for more comprehensive link-
age of pathological, clinical and molecular–biological
tumour features.
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